Enlivex Therapeutics Ltd
ENLV1.000USD
-0.030-2.92%
Cierre 11/05, 16:00（ET）Cotizaciones retrasadas 15 min
23.86MCap. mercado
PérdidaP/E TTM
Más Datos de Enlivex Therapeutics Ltd Compañía
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Información de Enlivex Therapeutics Ltd
Símbolo de cotizaciónENLV
Nombre de la empresaEnlivex Therapeutics Ltd
Fecha de salida a bolsaJul 30, 2014
Director ejecutivoDr. Oren Hershkovitz, Ph.D.
Número de empleados36
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
Dirección14 Einstein St.
CiudadNESS-ZIONA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal7403618
Teléfono97286623301
Sitio Webhttps://www.enlivex.com/
Símbolo de cotizaciónENLV
Fecha de salida a bolsaJul 30, 2014
Director ejecutivoDr. Oren Hershkovitz, Ph.D.
Ejecutivos de Enlivex Therapeutics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
Dr. Oren Hershkovitz, Ph.D.
Dr. Oren Hershkovitz, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Baruch Halpert
Mr. Baruch Halpert
Director
Director
--
--
Sangwoo Lee
Sangwoo Lee
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 26 de oct
Actualizado: dom., 26 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Armistice Capital LLC
5.82%
Novik (Shai A)
3.54%
Millennium Management LLC
2.52%
Citizens Financial Group, Inc.
0.95%
Morgan Stanley Smith Barney LLC
0.90%
Otro
86.27%
Accionistas
Accionistas
Proporción
Armistice Capital LLC
5.82%
Novik (Shai A)
3.54%
Millennium Management LLC
2.52%
Citizens Financial Group, Inc.
0.95%
Morgan Stanley Smith Barney LLC
0.90%
Otro
86.27%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
9.03%
Individual Investor
4.53%
Investment Advisor
2.09%
Research Firm
0.34%
Investment Advisor/Hedge Fund
0.05%
Otro
83.97%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
44
2.83M
11.67%
-522.40K
2025Q2
48
4.29M
17.99%
-279.61K
2025Q1
51
5.97M
25.02%
-258.45K
2024Q4
49
6.10M
27.74%
+737.29K
2024Q3
43
5.25M
23.90%
+285.76K
2024Q2
47
4.79M
22.40%
+1.35M
2024Q1
46
3.03M
14.05%
-328.65K
2023Q4
48
2.85M
15.31%
-503.64K
2023Q3
50
3.93M
21.15%
-597.01K
2023Q2
52
3.97M
21.39%
-603.59K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Armistice Capital LLC
1.41M
5.82%
-368.63K
-20.69%
Jun 30, 2025
Novik (Shai A)
858.77K
3.54%
+84.74K
+10.95%
Mar 31, 2025
Millennium Management LLC
612.20K
2.52%
-56.81K
-8.49%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
219.15K
0.9%
-10.58K
-4.61%
Jun 30, 2025
Havron (Abraham)
181.46K
0.75%
+1.92K
+1.07%
Mar 31, 2025
Renaissance Technologies LLC
168.39K
0.69%
-12.90K
-7.11%
Jun 30, 2025
Jane Street Capital, L.L.C.
61.05K
0.25%
-19.71K
-24.40%
Jun 30, 2025
Hershkovitz (Oren Ph.D.)
42.05K
0.17%
+16.55K
+64.92%
Mar 31, 2025
Sigma Investment Counselors, Inc.
28.00K
0.12%
--
--
Jun 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
